Amanda Ferrier Joins LumaBridge as Chief Operating Officer

SAN ANTONIO--(BUSINESS WIRE)-- LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to novel cancer therapies, today announced the appointment of Amanda Ferrier as Chief Operating Officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230807587831/en/

Amanda Ferrier Joins LumaBridge as Chief Operating Officer (Photo: Business Wire)

Ms. Ferrier brings over 20 years of clinical operations experience in oncology to LumaBridge. Her clinical operations expertise comes from both CROs and sponsor companies including Ilex Oncology; ArQule, Inc.; ICON; Ockham Oncology; PPD; CinRx/MedPace and most recently, ORA, Inc. She holds a B.S. in Nursing from The University of Texas – Health Science Center, a B.S. in Zoology/Biology from Texas A&M, and she is completing coursework for her M.B.A. from Suffolk University.

“Amanda is a great addition to the LumaBridge team as we continue to grow our oncology focused CRO,” said David Boyle, Chief Executive Officer of LumaBridge. “Her background as a registered nurse and in clinical operations, leadership and project management experience are all an excellent fit for our path forward.”

“I am thrilled to be joining the LumaBridge team. The company has a strong scientific foundation and an extremely talented management team that uniquely positions LumaBridge within the CRO environment,” said Amanda Ferrier. “As an RN and patient advocate, the opportunity to help accelerate the drug development process and identify better, more efficacious drugs for the global oncology patient population is incredibly exciting. This focus is top of mind for our team as LumaBridge moves to the next level in organizational growth.”

Ms. Ferrier succeeds current COO, Lori McDermott, who will remain with LumaBridge during a transition period.

“We want to thank Lori McDermott for her leadership role in helping to develop LumaBridge, our culture of high performing teams, and our focus on high-quality service to our sponsors,” said Dr. George Peoples, Founder and Executive Chairman. “We are confident that Amanda will build on this work, bringing energy, professionalism and experience to the company’s next phase of growth.”

About LumaBridge

LumaBridge is a specialty clinical research organization (CRO) focused on creating innovative clinical trial solutions for biopharma companies. Founded in 2014 as Cancer Insight, the company offers customized clinical trial guidance, strategic partnership, and personalized attention to each sponsor, accelerating the development of potential therapies.

LumaBridge builds on the success and experience of a seasoned team, led by Dr. George Peoples, to support drug development, accelerating therapies to patients, and guiding biopharma companies through clinical and regulatory pathways. As part of their comprehensive CRO services, LumaBridge offers consultation on trial design and clinical development strategy.

For more information, visit lumabridge.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230807587831/en/